摘要
目的:探讨复方黄芩甙制剂(Co-baicalin)治疗实验性自身免疫性脑脊髓炎(EAE)的有效性及其作用机制。方法:应用髓鞘脂质蛋白(PLP)139-151免疫SJL/J小鼠诱发慢性复发缓解性EAE模型,研究复方黄芩甙制剂对PLP139-151诱导的小鼠淋巴结细胞及脾细胞CD3、CD4、CD8及趋化因子受体CCR5的表达的影响,并通过神经功能评分观察复方黄芩甙制剂治疗EAE的有效性。结果:复方黄芩甙制剂治疗后,小鼠淋巴结细胞和脾细胞CD3、CD8阳性细胞百分比升高;而CD4、CCR5和CD4/CD8百分比下降,和对照组比较具有统计学意义(P<0.001)。复方黄芩甙制剂治疗组和强的松治疗组之间未见显著性差异(P>0.05)。此外复方黄芩甙制剂能够有效改善EAE小鼠神经功能评分(P<0.01)。结论:复方黄芩甙制剂可有效降低炎性细胞CD4阳性细胞数和CD4/CD8比例,下调CCR5的表达,为复方黄芩甙制剂用于临床多发性硬化的治疗提供了实验依据。
Objective： To explore the therapeutic effects of co-baicalin on experimental autoimmune encephalomyelitis（EAE） and its mechanism. Metbods：EAE was induced by PLP139-151 in SJL/J mice. The effects of Co-baicalin on the expression of CD3,CD4, CD8 and CCR5 of the lymph node （LN） cells and splenocyte in EAE mice were measured by using flow cytometry. Results： The percentage of CD3 and CD8 positive cells of LN and splenocyte in mice treated with Co-baicalin was significantly increased. However, the percentage of CD4 and CCR5 and the ratio of CD4/CD8 was significantly decreased compared with the control group. Mice receiving Co-baicalin treatment had significantly improved clinical outcomes compared with control group（P 〈 0.01 ）. Conclusion： Co-baicalin can effectively treat EAE mice by decreasing the percentage of CD4 and CCR5-positive cells and the ratio of CD4/CD8.
出处
《南京医科大学学报（自然科学版）》
CAS
CSCD
北大核心
2005年第12期887-889,共3页
Journal of Nanjing Medical University(Natural Sciences)
